-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
PerkinElmer, Inc. (NYSE:PKI) Stock Holdings Cut by Steigerwald Gordon & Koch Inc.
PerkinElmer, Inc. (NYSE:PKI) Stock Holdings Cut by Steigerwald Gordon & Koch Inc.
Steigerwald Gordon & Koch Inc. decreased its holdings in shares of PerkinElmer, Inc. (NYSE:PKI – Get Rating) by 0.1% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 110,240 shares of the medical research company's stock after selling 142 shares during the quarter. PerkinElmer comprises about 2.7% of Steigerwald Gordon & Koch Inc.'s investment portfolio, making the stock its 8th largest position. Steigerwald Gordon & Koch Inc.'s holdings in PerkinElmer were worth $15,678,000 at the end of the most recent quarter.
A number of other hedge funds also recently bought and sold shares of the business. Allworth Financial LP increased its position in PerkinElmer by 14,100.0% during the first quarter. Allworth Financial LP now owns 284 shares of the medical research company's stock valued at $50,000 after acquiring an additional 282 shares during the last quarter. Covestor Ltd increased its position in PerkinElmer by 25.1% during the first quarter. Covestor Ltd now owns 359 shares of the medical research company's stock valued at $63,000 after acquiring an additional 72 shares during the last quarter. MV Capital Management Inc. increased its position in PerkinElmer by 1,085.1% during the first quarter. MV Capital Management Inc. now owns 557 shares of the medical research company's stock valued at $97,000 after acquiring an additional 510 shares during the last quarter. Ellevest Inc. increased its position in PerkinElmer by 35.3% during the first quarter. Ellevest Inc. now owns 716 shares of the medical research company's stock valued at $125,000 after acquiring an additional 187 shares during the last quarter. Finally, Harvest Fund Management Co. Ltd increased its position in PerkinElmer by 128.4% during the first quarter. Harvest Fund Management Co. Ltd now owns 765 shares of the medical research company's stock valued at $133,000 after acquiring an additional 430 shares during the last quarter. Hedge funds and other institutional investors own 77.06% of the company's stock.
Get PerkinElmer alerts:Insider Transactions at PerkinElmer
In other news, insider Andrew Okun sold 3,173 shares of the firm's stock in a transaction that occurred on Monday, August 1st. The shares were sold at an average price of $165.42, for a total transaction of $524,877.66. Following the sale, the insider now owns 6,391 shares of the company's stock, valued at approximately $1,057,199.22. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider Andrew Okun sold 3,173 shares of PerkinElmer stock in a transaction on Monday, August 1st. The shares were sold at an average price of $165.42, for a total value of $524,877.66. Following the sale, the insider now owns 6,391 shares of the company's stock, valued at approximately $1,057,199.22. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Daniel R. Tereau sold 5,700 shares of PerkinElmer stock in a transaction on Friday, July 22nd. The shares were sold at an average price of $145.14, for a total transaction of $827,298.00. Following the completion of the sale, the insider now directly owns 13,380 shares in the company, valued at approximately $1,941,973.20. The disclosure for this sale can be found here. Insiders have sold 13,898 shares of company stock valued at $2,083,263 in the last 90 days. 0.52% of the stock is currently owned by company insiders.
Wall Street Analysts Forecast Growth
PKI has been the topic of a number of analyst reports. Stifel Nicolaus cut shares of PerkinElmer from a "buy" rating to a "hold" rating and cut their price objective for the company from $190.00 to $170.00 in a research report on Thursday, August 18th. Credit Suisse Group assumed coverage on shares of PerkinElmer in a report on Wednesday, August 24th. They issued a "neutral" rating and a $175.00 price target on the stock. Barclays cut their price target on shares of PerkinElmer from $149.00 to $140.00 and set an "underweight" rating on the stock in a report on Monday, September 12th. UBS Group assumed coverage on shares of PerkinElmer in a report on Wednesday, July 20th. They issued a "buy" rating and a $160.00 price target on the stock. Finally, Bank of America lowered shares of PerkinElmer from a "buy" rating to a "neutral" rating and set a $178.00 price objective for the company. in a research note on Tuesday, August 2nd. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $162.50.PerkinElmer Stock Down 1.4 %
Shares of PKI stock traded down $1.81 during mid-day trading on Thursday, hitting $124.14. 10,220 shares of the stock traded hands, compared to its average volume of 672,207. The stock has a market cap of $15.67 billion, a P/E ratio of 23.59, a P/E/G ratio of 0.35 and a beta of 1.14. The stock's fifty day moving average is $143.28 and its two-hundred day moving average is $150.73. PerkinElmer, Inc. has a 52-week low of $125.52 and a 52-week high of $203.16. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.02 and a quick ratio of 1.42.
PerkinElmer (NYSE:PKI – Get Rating) last released its quarterly earnings results on Monday, August 1st. The medical research company reported $2.32 EPS for the quarter, beating the consensus estimate of $2.01 by $0.31. The business had revenue of $1.23 billion during the quarter, compared to analyst estimates of $1.20 billion. PerkinElmer had a net margin of 13.21% and a return on equity of 16.68%. The company's quarterly revenue was up .1% on a year-over-year basis. During the same period in the prior year, the firm posted $2.83 earnings per share. Equities analysts predict that PerkinElmer, Inc. will post 7.83 EPS for the current year.
PerkinElmer Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 11th. Stockholders of record on Friday, October 21st will be paid a dividend of $0.07 per share. The ex-dividend date of this dividend is Thursday, October 20th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.23%. PerkinElmer's payout ratio is 5.24%.
PerkinElmer Profile
(Get Rating)
PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services.
See Also
- Get a free copy of the StockNews.com research report on PerkinElmer (PKI)
- The Institutions Hold On To Darden Restaurants International
- What Steelcase's Earnings Say About the Return to the Office?
- Is The Golden Age Of Homebuilding Already Over?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Want to see what other hedge funds are holding PKI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PerkinElmer, Inc. (NYSE:PKI – Get Rating).
Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.
Steigerwald Gordon&Koch Inc.在向美国证券交易委员会(Securities&Exchange Commission)提交的最新披露中称,该公司第二季度减持了PerkinElmer,Inc.(纽约证券交易所代码:PKI-GET评级)的股票0.1%。该机构投资者在本季度出售了142股后,持有这家医疗研究公司110,240股股票。PerkinElmer在S的投资组合中所占比例约为2.7%,这使该股成为其第八大投资组合。截至最近一个季度末,S持有的PerkinElmer价值15,678,000美元。
其他一些对冲基金最近也买入和卖出了该公司的股票。Allworth Financial LP在第一季度将其在PerkinElmer的头寸增加了14,100.0%。Allworth Financial LP现在拥有284股这家医疗研究公司的股票,价值5万美元,在上个季度又购买了282股。Covestor Ltd在第一季度将其在PerkinElmer的头寸增加了25.1%。Covestor Ltd现在拥有这家医疗研究公司359股股票,价值6.3万美元,此前在上个季度又购买了72股。MV Capital Management Inc.在第一季度将其在PerkinElmer的头寸增加了1085.1%。MV Capital Management Inc.现在持有这家医疗研究公司557股股票,价值97,000美元,此前该公司在上个季度增持了510股股票。Ellevest Inc.在第一季度将其在PerkinElmer的头寸增加了35.3%。Ellevest Inc.现在持有这家医疗研究公司716股股票,价值12.5万美元,该公司在上个季度增持了187股。最后,嘉实基金管理有限公司在第一季度将其在PerkinElmer的头寸增加了128.4%。嘉实基金管理有限公司在上个季度增持了430股后,现在持有这家医学研究公司765股股票,价值13.3万美元。对冲基金和其他机构投资者持有该公司77.06%的股份。
到达PerkinElmer警报:PerkinElmer的内幕交易
在其他新闻方面,内部人士安德鲁·奥肯在8月1日星期一的一笔交易中出售了3173股该公司的股票。这些股票以165.42美元的平均价格出售,总成交金额为524,877.66美元。出售后,这位内部人士现在拥有该公司6,391股股票,价值约1,057,199.22美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可通过美国证券交易委员会网站。在相关新闻中,内部人士安德鲁·奥肯在8月1日(星期一)的一笔交易中出售了3173股PerkinElmer股票。这些股票的平均价格为165.42美元,总价值为524,877.66美元。出售后,这位内部人士现在拥有该公司6,391股股票,价值约1,057,199.22美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可通过此超链接。此外,内部人士Daniel·R·特罗在7月22日(星期五)的一次交易中出售了5,700股PerkinElmer股票。这些股票以145.14美元的平均价格出售,总成交金额为827,298.00美元。出售完成后,该内部人士现在直接拥有该公司13,380股,价值约1,941,973.20美元。关于这次销售的披露可以找到这里。在过去的90天里,内部人士已经出售了13,898股公司股票,价值2,083,263美元。公司内部人士目前持有该公司0.52%的股份。
华尔街分析师预测经济增长
公钥基础设施已经成为许多分析师报告的主题。Stifel Nicolaus在8月18日周四发布的一份研究报告中,将PerkinElmer的股票评级从“买入”下调至“持有”,并将该公司的目标价从190.00美元下调至170.00美元。瑞士信贷集团在8月24日星期三的一份报告中对PerkinElmer的股票进行了报道。他们对该股给予了“中性”评级和175.00美元的目标价。巴克莱将PerkinElmer的股票目标价从149.00美元下调至140.00美元,并在9月12日周一的一份报告中将该股的评级定为“减持”。瑞银集团在7月20日星期三的一份报告中对PerkinElmer的股票进行了报道。他们对该股给予了“买入”评级和160.00美元的目标价。最后,美国银行将PerkinElmer的股票评级从“买入”下调至“中性”,并为该公司设定了178.00美元的目标价。在8月2日星期二的一份研究报告中。一名投资分析师对该股的评级为卖出,五名分析师给出了持有评级,四名分析师给出了该公司股票的买入评级。根据MarketBeat的数据,该公司目前的平均评级为持有,共识目标价为162.50美元。PerkinElmer股价下跌1.4%
周四午盘,PKI股价下跌1.81美元,至124.14美元。该股有10,220股易手,而其平均成交量为672,207股。该股市值156.7亿美元,市盈率23.59倍,市盈率0.35倍,贝塔系数1.14。该股的50日移动均线切入位为143.28美元,200日移动均线切入位为150.73美元。PerkinElmer,Inc.的52周低点为125.52美元,52周高位为203.16美元。该公司的债务权益比为0.63,流动比率为2.02,速动比率为1.42。
PerkinElmer(纽约证券交易所代码:PKI-GET Rating)最近一次发布季度收益报告是在8月1日星期一。这家医疗研究公司公布本季度每股收益为2.32美元,比普遍预期的2.01美元高出0.31美元。该业务本季度营收为12.3亿美元,而分析师预期为12.亿美元。PerkinElmer的净利润率为13.21%,股本回报率为16.68%。该公司季度营收同比增长1.1%。去年同期,该公司公布的每股收益为2.83美元。股票分析师预测,PerkinElmer,Inc.本年度每股收益将达到7.83美元。
PerkinElmer宣布分红
该公司最近还披露了季度股息,将于11月11日(星期五)支付。10月21日(星期五)登记在册的股东将获得每股0.07美元的股息。本次股息除息日期为10月20日(星期四)。这意味着年化股息为0.28美元,股息收益率为0.23%。PerkinElmer的派息率为5.24%。
PerkinElmer配置文件
(获取评级)
PerkinElmer,Inc.为全球诊断、生命科学和应用服务市场提供产品、服务和解决方案。它通过两个部门运行:发现和分析解决方案以及诊断。发现与分析解决方案部门提供一整套解决方案,包括试剂、信息学、检测和成像技术,使科学家能够加强生命科学研究市场的研究突破,以及合同研究和实验室服务。
另请参阅
- 免费获取StockNews.com关于PerkinElmer的研究报告(PKI)
- 这些机构持有达顿餐饮国际公司的股份
- 斯蒂尔凯斯的收益说明了他重返办公室的原因吗?
- 住房建设的黄金时代已经结束了吗?
- 这三大股利支付者也拥有强劲的价格增长
- 天然气价格继续回升,这些股票应该会受益
想看看还有哪些对冲基金持有PKI吗?访问HoldingsChannel.com获取PerkinElmer,Inc.(纽约证券交易所代码:PKI-GET Rating)的最新13F文件和内幕交易。
接受PerkinElmer Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对PerkinElmer和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧